RnRMarketResearch.com adds “Primary Progressive Multiple Sclerosis (PPMS) – Pipeline Review, H1 2015” to its store. The report provides an overview of the Primary Progressive Multiple Sclerosis (PPMS)’s therapeutic pipeline.

Dallas, TX -- (SBWire) -- 06/03/2015 --The report "Primary Progressive Multiple Sclerosis (PPMS) – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Primary Progressive Multiple Sclerosis (PPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Complete report on H1 2015 pipeline review of Primary Progressive Multiple Sclerosis (PPMS) with 23 market data tables and 13 figures, spread across 71 pages is available at http://www.rnrmarketresearch.com/primary-progressive-multiple-sclerosis-ppms-pipeline-review-h1-2015-market-report.html

Companies discussed in this Primary Progressive Multiple Sclerosis (PPMS) – Pipeline Review, H1 2015 report include AB Science, Genzyme Corporation, Glialogix, Inc., Innate Immunotherapeutics Limited, Kyorin Pharmaceutical Co., Ltd., MedDay, Santhera Pharmaceuticals Holding AG, Teva Pharmaceutical Industries Limited.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are GLX-1112, GZ-402668, ibudilast, idebenone, laquinimod sodium, masitinib, MD-1003, MIS-416, Small Molecules for Multiple Sclerosis.

Order a purchase copy of this report
http://www.rnrmarketresearch.com/contacts/purchase?rname=365330
(This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases: Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting; Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

List of Tables
Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H1 2015 7
Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by AB Science, H1 2015 14
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Genzyme Corporation, H1 2015 15
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Glialogix, Inc., H1 2015 16
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Innate Immunotherapeutics Limited, H1 2015 17
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 18
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by MedDay, H1 2015 19
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2015 20
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Primary Progressive Multiple Sclerosis (PPMS) Therapeutics - Recent Pipeline Updates, H1 2015 49
Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products, H1 2015 68

List of Figures
Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H1 2015 7
Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Top 10 Targets, H1 2015 23
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Top 10 Routes of Administration, H1 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28
Number of Products by Top 10 Molecule Types, H1 2015 29
Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

Explore more reports on Ophthalmology therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/ophthalmology-therapeutics

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.